A urease-based enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of reagin antibodies in serum. Visuwell Reagin (ADI Diagnostics Inc., Rexdale, Ontario, Canada) is a non-treponemal screening test for the serodiagnosis of syphilis which has the benefits of large batch testing, automatability, and objective interpretation of results. Unheated, undiluted sera are incubated in 96-well microtiter plates coated with a modified cardiolipin-lecithin-cholesterol antigen. Antibody bound to the plate is detected by an anti-human immunoglobulin G-urease conjugate. The procedure consists of three steps, with a total test time of 60 min. Visuwell Reagin ELISA was compared with the Venereal Disease Research Laboratory (VDRL) test and the reagin screening test (RST) with the following results. For ELISA versus the VDRL test, the sensitivities for untreated syphilis (n = 37) were 97.3% for both ELISA and the VDRL test, the confirmatory positive values (n = 79) were 84.8% for ELISA and 72.2% for the VDRL test, and the specificities for normal samples (n = 1,327) were 98.8% for ELISA and 99.5% for the VDRL test. For ELISA versus RST, the sensitivities for untreated syphilis (n = 57) were 94.7% for ELISA and 87.7% for RST, the confirmatory positive values (n = 26) were 96.2% for ELISA and 92.3% for RST, and the specificities for normal samples (n = 1,891) were 99.6% for ELISA and 99.3% for RST. The overall concordance values of ELISA with VDRL test and RST were 96.7 and 97.9%, respectively. The specificity of ELISA compared with that of RST may be underestimated, since confirmatory data were not available for all apparent false-positive samples. The Visuwell Reagin had increased sensitivity and similar specificity compared with flocculation tests.
Syphilis is typically serodiagnosed by using two types of laboratory tests, non-treponemal screening tests which detect antibodies against lipid or reagin, and treponemal tests which confirm the presence of antibodies specific to treponemal surface antigens. Non-treponemal tests are based on the Venereal Disease Research Laboratory (VDRL) antigen, which reacts with reagin antibodies formed by the host in response to lipid released from damaged host cells and from the treponeme itself (5, 7) . Commercially available nontreponemal tests, such as the VDRL test, unheated serum reagin, rapid plasma reagin (RPR), reagin screening test (RST), and toluidine red unheated serum test, are flocculation tests employing a cardiolipin-lecithin-cholesterol-based antigen (8, (10) (11) (12) . Such tests, although inexpensive, are difficult to interpret, particularly for weakly reactive sera, and have limited potential for high-volume testing and automation (6, 7) .
We have developed a non-treponemal enzyme-linked immunosorbent assay (ELISA) which incorporates a modified version of the VDRL antigen and provides the versatility of the ELISA format. The potential diagnostic advantages of the ELISA format relative to flocculation tests are well documented (2, 6, 13) . Pedersen et al. (9) described the first ELISA for the detection of immunoglobulin G (IgG) and IgM antibodies to the VDRL antigen. The IgG sensitivity of this ELISA (96.6%, n = 118) was reported to be equivalent to those of traditional non-treponemal tests for sera from patients with untreated syphilis, and the specificity was found to be 99.6% with sera from persons without syphilis (n = 1,008).
In this report we describe the antigen preparation, assay format, and component stability of the Visuwell Reagin (ADI Diagnostics Inc., Rexdale, Ontario, Canada), a non-trepo-* Corresponding author.
nemal IgG ELISA screen for syphilis. Initial evaluation indicates that the Visuwell Reagin offers increased sensitivity and similar specificity compared with flocculation tests.
MATERIALS AND METHODS
Reagin antigen plates. Round-bottom polyvinyl chloride microdilution wells (A/S Nunc, Roskilde, Denmark) were coated with 50 ,ul of an absolute ethanol solution containing 0.0006% (wt/vol) cardiolipin (Sigma Chemical Co., St. Louis, Mo.), 0.0042% (wt/vol) lecithin (Sigma), 0.09% (wt/ vol) cholesterol (USP grade; Sigma), and 0.0042% (wt/vol) sorbitol (BDH, Toronto, Ontario, Canada). The ethanol was evaporated, and the dried plates were sealed in foil pouches with desiccant (Multidesiccant, Buffalo, N.Y.) and stored at ambient temperature until used.
Conjugate. Sera from rabbits immunized with human IgG(Fc) (Jackson Immunoresearch, West Grove, Pa.) were purified by using a protein A-Sepharose (Cl-4B; Pharmacia, Dorval, Quebec, Canada) column by the method of Fuller et al. (4 (1) . Sixty coded aliquots were tested, six per day, along with routine specimens on 10 testing days (five of which were consecutive) throughout the evaluation period. All reactive and nonreactive samples gave identical qualitative results during this testing protocol.
(iii) Site C. Testing at site C was performed by ADI Diagnostics personnel in a blind study, while VDRL, RPR, MHA-TP and FTA-ABS testing was done by CDC personnel. A total of 311 serum samples were tested by these five procedures (Table 3 ). In the untreated, primary syphilis category, Visuwell Reagin detected an additional serum sample that was undetected by the other testing methods. In the untreated, secondary syphilis category, one serum sample was nonreactive by Visuwell Reagin and weakly reactive by the VDRL and RPR tests. A weakly reactive result is unusual for this stage of disease. The overall sensitivity for untreated syphilis was the same for the three screening tests (97.3%, n = 37). In the treated syphilis category, reactivities of primary and secondary syphilitic sera were similar for the VDRL, RPR, and Visuwell Reagin tests, whereas differences were observed for treated, latent syphilitic sera. The Visuwell Reagin test had 12 more nonreactive serum samples than did the VDRL test and 8 more nonreactive serum samples than the RPR assay. Of the 12 Visuwell Reagin nonreactive serum samples, 8 were from patients who had received treatment more than 2 years previously, 1 was from a patient who had received treatment 10 months previously, and 3 were from patients treated 1 month previously.
In the nonsyphilitic category, each screening test was nonreactive for 78 serum samples of blood donors with no history of syphilis. Fewer serum samples from patients with diseases other than syphilis were reactive by Visuwell Reagin than by either the VDRL test or the RPR test. The four serum samples reactive by Visuwell Reagin were from patients with systemic lupus erythematosus and were also reactive by VDRL and RPR tests. Of 44 biological falsepositive samples for the VDRL test, 11 were nonreactive by Visuwell Reagin. Visuwell Reagin exhibited a specificity of 78.5% for the entire panel of nonsyphilitic sera compared with specificities of 68.0 and 73.2% for the VDRL and RPR tests, respectively.
Absorbance values (A620s) of sera tested at site C are plotted in Fig. 1 as a function of sample type. Note that for the samples from normal patients, the A620 readings were well below the cutoff value for A620 of 0.08. Conversely, 94% of the samples from patients with untreated syphilis exhibited A620 readings at least four times the cutoff level. Only 50% of the biological false-positives and 74% of the samples from patients with treated syphilis exhibited A620 values four times the cutoff value.
Stability of Visuwell Reagin components. All Visuwell
Reagin components retained 100% reactivity for at least 6 months of storage at 4°C, the recommended storage temperature (data not shown). At ambient temperature, the sub- 
